Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results, Misses Estimates By $0.78 EPS

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78), Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million during the quarter, compared to analyst estimates of $44.64 million.

Arcturus Therapeutics Stock Down 3.0 %

Shares of Arcturus Therapeutics stock traded down $0.44 on Monday, hitting $14.12. 266,875 shares of the company traded hands, compared to its average volume of 416,814. Arcturus Therapeutics has a 12-month low of $13.58 and a 12-month high of $45.00. The company has a market cap of $382.33 million, a PE ratio of -6.37 and a beta of 2.96. The company has a 50-day moving average price of $16.95 and a 200 day moving average price of $18.55.

Wall Street Analysts Forecast Growth

ARCT has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a research report on Monday. HC Wainwright reduced their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research report on Friday. Wells Fargo & Company cut their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the company a "buy" rating in a report on Monday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $59.20.

Remove Ads

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.